世界のエボラ診断、治療薬、ワクチン市場

thumbnail.ashxfileD3a5cinetpub5cwwwroot5cwww.visiongain.com5creports5cimg5cimg1351
◆英語タイトル:The Ebola Report: 2014 Epidemic And R&D Drug Prospects
◆発行会社/調査会社:visiongain
◆商品コード:VGAIN4120210
◆発行日:2014年11月
◆調査対象地域:グローバル
◆産業分野:医療
◆ページ数:115
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single user licence(1名使用、1年)GBP1,799 ⇒換算¥259,056見積依頼/購入/質問フォーム
Dept Licence(5名まで共有可、1年)GBP2,999 ⇒換算¥431,856見積依頼/購入/質問フォーム
Site Licence(全社内共有可、PDF制限なし)GBP4,999 ⇒換算¥719,856見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongain社の日本における正規販売代理店です。同社発行の市場調査資料のご購入、委託調査サービスに関するお問い合わせは弊社までお願い致します。
visiongain社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[世界のエボラ診断、治療薬、ワクチン市場]についてメールでお問い合わせはこちら
当調査レポートでは、世界のエボラ診断、治療薬、ワクチン市場について調査・分析し、イントロダクション、エボラ診断薬開発パイプライン、エボラ治療薬開発パイプライン、エボラワクチン開発パイプライン、地域別市場分析、市場環境分析、専門家の見解、主要企業分析データなどをお届けいたします。
*** レポート概要(サマリー)***

The Ebola Report – new study showing you trends and R&D progress
What opportunities are there in a market for Ebola diagnostics, prevention, and treatment? What are the commercial prospects for this market and related technologies? Visiongain’s new report shows market potential for products and other trends, discussing data, opportunities and prospects.

Our new 115 page report provides 40 tables, charts, and graphs. Discover the R&D prospects of products in the pipeline and their future market potential. Our new study lets you assess the leading candidates in the race for entry into the market for Ebola diagnostics, vaccines, and treatments. You will see interviews, trends, and opportunities that may arise.

Future outlook and other analyses show you commercial prospects
Our new study provides you with original analyses, with business outlooks and developments. Discover qualitative analyses, product profiles and commercial developments. Read the full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
• Prof. Sunetra Gupta, Professor of Theoretical Epidemiology, University of Oxford
• Dr Derek Gatherer, Division of Biomedical and Life Sciences, Lancaster University

You find prospects for the R&D pipeline of key submarkets
What is happening in the R&D pipeline for Ebola diagnostics, drugs and vaccines? You see developmental trends, gaining insight into the current products in development. In addition to analyses of currently used Ebola pharma/Medtech products, you see analyses for the pipeline of these three product categories:
• Ebola diagnostics
• Ebola treatments
• Ebola vaccines

Drugs that can significantly reduce the high mortality rate associated with infections with the Ebola virus whilst reducing the many grievous symptoms will achieve success. Vaccines aimed at protecting front-line healthcare workers treating patients infected with the Ebola virus will prove successful and financially viable to developers and manufacturers

Our investigation shows business research and analyses with individual product evaluations and discussions. You find the dynamics of the industry and assess its potential growth, seeing agents likely to achieve the most success.

See insightful analysis for products
What are the characteristics of the most promising drugs and vaccines being developed or tested to treat or prevent Ebola? How will promising products currently in the pipeline perform once they are launched? Our study profiles promising Ebola drugs including these:
• ZMapp
• Brincidofivir
• BCX4430
• AVI-7537
• Lamivudine
• Favipiravir
• TKM-Ebola

You will see what is happening, understanding trends, challenges and opportunities. Discover features and profiles for Ebola vaccines currently under development. These include:
• VesiculoVax
• GSK’s ChAd vaccine
• New Link Genetic Corp’s rVSV vaccine
• Johnson & Johnson/ Bavarian Nordic AdVac/ MVA-BN Technology-based vaccine

What are the prospects for the various regions and countries?
Which countries are most at risk? Which countries are best prepared to tackle potential cases of Ebola? Regulatory approvals and the trends being observed for some products getting fast tracked will play a crucial role in shaping the future of the market for Ebola drugs and vaccines. Our analyses show a rapid uptake for products targeting the Ebola virus and Ebola virus disease on the back of the devastation caused by the Ebola virus disease outbreak in West Africa in 2014. In particular, the countries in North America and Europe will look to stock up on Ebola drugs and vaccines to counter the risk of Ebola virus disease spreading into the region. Furthermore, the potential threat of the Ebola virus being used as a possible bio-terror agent will also influence the uptake and launch of new drugs.

Regulatory, demographic, and commercial developments worldwide will influence the markets both in the established North American and Western European economies, and the fast-rising emerging markets.

Discover R&D efforts from leading pharmaceutical companies
Rising demand for safe and effective Ebola drugs and diagnostics, increasing healthcare coverage, increased commitment to product testing and a strong R&D pipeline will expand the market for these products in the near future.

Our work shows you products from various organisations that hold great potential for diagnosing, preventing, and treating Ebola. These organisations include:
• BioCryst Pharmaceuticals
• Chimerix Inc
• GlaxoSmithKline
• Johnson & Johnson
• Mapp BioPharma
• New Link Genetic Corporation
• Profectus BioSciences
• Serepta Therapeutics
• Tekmira Pharmaceuticals

*** レポート目次(コンテンツ)***

1. Report Overview
1.1 Ebola Virus And Ebola Virus Disease: An Overview
1.2 Ebola Diagnostic Tools And The Global Pipeline For Ebola Vaccines And Treatments
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered By This Analytical Report
1.6 Who Is This Report For?
1.7 Methodology
1.8 Associated Reports
1.9 About Visiongain

2. An Introduction To Ebola: Origin, History, and Epidemiology
2.1 The Ebola Virus
2.1.1 Ebola Virus Replication Mechanism – Host Cell Typically Held Hostage
2.2 Ebola Virus Disease – A Lethal Haemorrhagic Disease
2.2.1 Symptoms of Ebola Virus Disease
2.2.2 Progression Over Time From Infection By Ebola Virus
2.3 Ebola Outbreaks – A Tumultuous History
2.3.1 Kikwit Ebola Outbreak Of 1995 – Mortality And Response
2.3.2 Post-1995 Outbreaks Of Ebola
2.4 Ebola Virus – Natural Reservoir And Mode Of Transmission
2.4.1 Molecular Mechanism of Ebolavirus Transmission
2.4.2 Wild-Life To Human Transmission
2.4.3 Human To Human Transmission

3. Ebola Outbreak Of 2014: Current Assessment and Projections for Future Incidence
3.1 Rapid Spread Of The Virus Aided By Rising Migration
3.1.1 Ebola Outside Of Africa – Does This Signal Possibility Of Global Spread?
3.1.2 Explosion Of New Ebola Cases In Late 2014 – Where Does This Leave Efforts To Curb The Spread Of The Virus?
3.2 Ro Calculations – A Method Of Predicting The Rate Of Ebola Spread
3.3 Containment Measures For Ebola Virus Spread In West Africa
3.3.1 Public Engagement As A Way Of Containing Ebola Spread
3.4 Downsides To The Strategies Currently In Place To Contain The Spread Of Ebola
3.5 Efforts To Monitor Incidence Flow And The Pattern Of Spread
3.6 Projections For Future Incidence Of Ebola Virus Disease (EVD)
3.7 Limitations To Forecasting EVD Incidence And Spread

4. Ebola Diagnostics: Currently Marketed Products And Pipeline Analysis, 2014
4.1 What are In Vitro Diagnostic (IVD) Tests?
4.2 Classifying In Vitro Diagnostics
4.2.1 The US Classification For Medical Devices
4.2.2 The EC (European Commission) Classification For Medical Devices
4.3 Regulations Surrounding The Use Of IVD Tests
4.4 Point Of Care Diagnostics Tools Are Necessary For Swift Ebola Containment
4.5 In Vitro Diagnostic Tests For Ebola
4.5.1 Immunochemistry – A Clearer Means Of Detecting Ebola Virus
4.6 Currently Used Diagnostic Tests For Ebola Virus
4.6.1 Enzyme-linked Immunosorbent Assay (ELISA)
4.6.1.1 ELISA Formats – Varying Modes Of Detection
4.6.1.2 ELISA As A Tool For Ebola Diagnosis
4.6.2 Reverse Transcription Polymerase Chain Reaction (RT-PCR)
4.6.3 Virus Isolation – Reliable Method Of Diagnosing Ebola
4.7 Issues Around The Currently Available Ebola Diagnostic Tools
4.8 Diagnostic Products In The Pipeline For Ebola
4.8.1 Corgenix Medical Corporation – Rapid Ebola Diagnostic Test Kit

5. Ebola Treatments: Pipeline Analysis, 2014
5.1 Ebola Drugs: Intensifying Efforts In Development Drive
5.2 BioCryst Pharmaceuticals – BCX4430
5.3 Chimerix Inc – Brincidofovir
5.4 Leaf BioPharma/ Mapp BioPharma/ Defyrus Inc – ZMapp
5.4.1 Development Efforts For ZMapp
5.5 Serepta Therapeutics – AVI-7537
5.5.1 Development Efforts For AVI-7537 & AVI-6002
5.6 Tekmira Pharmaceuticals – TKM-Ebola
5.6.1 Development Efforts For TKM-Ebola
5.6.2 Progress Of Clinical Trials For TKM-Ebola
5.6.3 Increasing TKM–Ebola Manufacturing Signals Positive Outlook For The Therapy
5.7 Toyama Chemical Co Ltd/ Fujifilm Holding Corp – Favipiravir
5.8 Viiv Healthcare – Lamivudine
5.9 Convalescent Serum

6. Ebola Vaccines: Pipeline Analysis, 2014
6.1 What Are Vaccines?
6.1.1 Paediatric Vaccines
6.1.2 Adult Prophylactic Vaccines
6.2 Will Routine Adult Vaccination Become A Reality Over The Next Decade?
6.2.1 Extensive Pipeline, But Adult Immunisation Still Needs to Become More Widely Established
6.3 GlaxoSmithKline – ChAd-EBOV Vaccine
6.3.1 Development Efforts For GSK/NIAID’s Ebola Vaccine
6.3.2 Future Plans For The Development Of GSK‘s Vaccine
6.3.3 Issues With The GSK/NIAID Ebola Vaccine
6.4 Johnson & Johnson/ Bavarian Nordic – AdVac/MVA-BN Technology-Based Ebola Vaccine
6.4.1 Development Efforts For J&J/Bavarian Nordic’s Ebola Vaccine
6.4.2 Johnson & Johnson’s Humanitarian Efforts During The 2014 Ebola Outbreak
6.5 NewLink Genetic Corporation/ PHAC – rVSV Vaccine
6.6 Profectus BioSciences – VesiculoVax
6.6.1 Development Efforts For VesiculoVax
6.6.2 Funding Flowing In For Development Of VesiculoVax
6.7 Where Does The Market For Ebola Vaccines Stand And Where Is It Going?
6.7.1 Regulations Around ‘Fill Capacity’ May Impact Future Use Of Ebola Vaccines
6.7.2 Factors That May Hinder Scaling Up Production Of Ebola Treatments

7. Economic And Socio-Political Impacts Of Ebola
7.1 The Economic Impact Of Ebola On The Three Worst-Hit Nations
7.1.1 Crippling Domestic Food Production Leading To Inflation
7.1.2 Impact Of The Ebola Outbreak On Manufacturing, Natural Resources, And Other Service Sectors
7.1.3 The Economic Impact Of The 2014 Ebola Outbreak On West Africa
7.1.4 Lax Border Control Contributing To The Spread Of Ebola
7.2 The Global Economic Impacts Of Ebola
7.3 The Economic Benefits Of An Ebola Drugs Market
7.4 Measures Being Implemented By US Authorities For Preventing The Spread Of Ebola
7.5 The Potential Spread Of Ebola In Asia And The Likely Socio-Economic Impacts
7.5.1 Evaluation Of India’s Preparedness For An Ebola Outbreak
7.5.2 China – How Prepared Is The World’s Most Populous Nation To Deal With Ebola
7.5.3 Japan Being Urged To Increase Its Response To The Fight Against Ebola
7.6 Ebola As A Potential Bioterrorism Threat
7.6.1 Criteria Used For Categorising Bio-terror Threats
7.6.2 Major Bio-terror/Bio-warfare Threats
7.6.2.1 Anthrax (Bacillus anthracis)
7.6.2.2 Botulism (Clostridium botulinum toxin)
7.6.2.3 Bubonic Plague (Yersinia pestis)
7.6.2.4 Ricin (Ricinus communis)
7.6.2.5 Smallpox (Variola major)
7.6.2.6 Tularaemia (Francisella tularensis)
7.6.2.7 Viral hemorrhagic Fevers – Ebola And Marburg Viruses
7.6.3 Bio-terrorism Preparedness
7.6.4 The Future Of Ebola As A Biodefense Threat

8. Humanitarian Efforts To Combat Ebola – Evaluation Of Response And Its Effectiveness
8.1 A Steady Increase In Humanitarian Relief For Ebola Over 2014
8.2 Governmental- And Non-Governmental Organisations Aiding In The Relief Effort To Combat Ebola
8.3 The Cost Of Running Ebola Treatment Centres In West Africa
8.4 Other Organisations And Their Pledges To The Ebola Relief Efforts In West Africa
8.5 Measures Being Implemented For Care In The Communities Affected By Ebola

9. Expert Opinions from Our Primary Research
9.1 Interview With Dr Derek Gatherer, Division Of Biomedical And Life Sciences At Lancaster University, UK.
9.1.1 Issues Around The Use Of Convalescent Blood Transfusion As A Treatment For EVD
9.1.2 An Evaluation Of ZMapp As A Drug For EVD
9.1.3 How Far Away Are Small Drug Molecules Being Developed From Entering The Market
9.1.3.1 Favipiravir And Cidofovir As Possible Treatments For EVD
9.1.3.2 Does BCX-4460’s Effectiveness In Non-Human Primates Translate To Possible Market Potential
9.1.4 The Trade-Off Between Modern Drug Design Technologies And Animal Models For Developing Drugs
9.1.5 On The Role That Viral Surface Proteins Play In The Development Of Vaccines Targeted At The Virus
9.1.6 Clinical Trials Planned For Ebola Vaccine In 2014/15 And The Logistical Plans Being Implemented
9.1.7 Ebola Preparedness: Assessments And other Processes Being Implemented To Prevent The Dissemination Of Ebola Virus
9.1.8 On How The Study Of Viral Phylogenetics Will Impact The Design Of Ebola Vaccines And Therapies
9.1.9 Is The Slowing Rate Of EVD Spread A Reliable Indicator Of The Ebola Outbreak Subsiding
9.1.10 The Southeastward Spread Of EVD In West Africa And The Implications For Countries In The Region
9.2 Interview With Professor Sunetra Gupta, Professor Of Theoretical Epidemiology, University Of Oxford, UK
9.2.1 Should We Worry More About Influenza Viruses Than We’ve Worried About Ebola
9.2.2 Global Connectedness – A Factor Increasing The Risk Of Ebola Spread?
9.2.3 Issues With Safety And Immunogenicity Tests For Vaccines Currently Being Developed
9.2.4 The Genomic Revolution – How New Information Streams Are Opening Doors To Novel Vaccine Designs
9.2.5 The Future Outlook For Development Of Vaccines Against Virus Such As Ebola

10. Conclusions
10.1 Overview Of The 2014 Ebola Outbreak – The Largest In History
10.2 Diagnostic Methods Used In Detecting Ebola Virus – More Rapid Technologies Needed
10.3 Drugs Being Developed To Combat Ebola – Issues Around Safety And Efficacy
10.4 Ebola Vaccines – For How Long Will The Protection Last?
10.5 Are Humanitarian Efforts Being Directed Towards Fighting The 2014 Ebola Outbreak Having The Desired Effects?
10.6 How Different Will The Socio-Political Landscape Of An Ebola-Free West Africa Be?

List of Tables
Table 1.1 EVD Incidence and Mortality In Guinea, Liberia, and Sierra Leone, 2014
Table 2.1 Ebola Genes and the Structural Proteins They Encode, 2014
Table 2.2 Selected Historical Outbreaks Of Ebola Disease: Year, Location, Number of Cases, and Fatality, 1976-2014
Table 3.1 Incidence Of Ebola In Europe and the US, 2014
Table 3.2 Ebola Incidence and Mortality in West Africa, 2014
Table 3.3 Countries Most Affected By Ebola And Their Recent Socio-Political Issues, 2014
Table 3.4 Public Engagement Strategies Being Used To Combat The Spread Of The Ebola Virus, 2014
Table 4.1 Advantages and Disadvantages of Point of Care Diagnostics, 2014
Table 4.2 Ebola Diagnostics: Currently Used Measures and R&D Pipeline, 2014
Table 4.3 Advantages and Disadvantages of the Direct and Indirect ELISA Detection Formats, 2014
Table 4.4 qPCR Detection Methods, 2014
Table 5.1 Ebola Treatments: Currently Used Measures and R&D Drugs Pipeline, 2014
Table 5.2 Molecular Components of ZMapp: Components, Manufacturers and Description, 2014
Table 5.3 Serepta Therapeutic’s Drug Pipeline Portfolio – Products, Development Phases and Indications, 2014
Table 6.1 Selected Vaccine Preventable Diseases: Associated Conditions, Incidence rates, and Mortality Rates, 2013
Table 6.2A Types of Vaccines and Their Description, 2014
Table 6.2B Types of Vaccines and Their Description, 2014 (Continued)
Table 6.3 Selected Adult Prophylactic Vaccine Products and Pipeline Developments: Products, Manufacturers and Indications, 2014
Table 6.4 Adult Prophylactic Vaccines: Market Drivers and Restraints, 2014
Table 6.5 Ebola Vaccines: R&D Pipeline, 2014
Table 6.6 NewLink Genetics Ebola Vaccines: Projected Production Capacity, 2015
Table 7.1 Categories Of Biological Agents Used in Warfare or Terror Attacks, 2014
Table 8.1 Available and Required Beds for Ebola Treatment Units in the three Worst Hit Countries, 2014
Table 8.2 Medical Response Sent To West Africa By Various Countries During The Ebola Crisis, 2014

List of Figures
Figure 1.1 EVD Incidence and Mortality In Guinea, Liberia, and Sierra Leone, 2014
Figure 1.2 The Ebola Report – Report Segmentation and Coverage, 2014
Figure 2.1 Diagrammatic Illusion Of The Structure Of The Ebola Virus, 2014
Figure 2.2 Cellular Replication Mechanism Used By Ebola Virus, 2014
Figure 2.3 Symptoms of Ebola Virus Disease, 2014
Figure 2.4 The Symptomatic Progression of Ebola Virus Disease, 2014
Figure 2.5 Kikwit: The Epicentre of the 1995 Ebola Outbreak In DR Congo
Figure 2.6 Diagrammatic Representation Of The Routes Of Ebola Transmission, 2014
Figure 3.1 Ebola Outbreak In West Africa: Outbreak Distribution Map, 2014
Figure 4.1 Formats of Enzyme Linked Immunosorbent Assay (ELISA), 2014
Figure 4.2 The Process of Reverse Transcription Polymerase Chain Reaction (RT-PCR), 2014
Figure 5.1 Structure of BCX4430
Figure 5.2 Structure of Active Brincidofivir
Figure 5.3 Structure of Favipiravir, 2014
Figure 5.4 Structure of Lamivudine, 2014
Figure 5.5 Diagrammatic Representation of Convalescent Serum, 2014
Figure 6.1 Global Mortality Due to Vaccine Preventable Diseases in Children Under Five, Breakdown by Disease (%), 2008
Figure 6.2 GSK’s Experimental ChAd Ebola Vaccine, 2014
Figure 7.1 Effect of the SARS Outbreak On Hong Kong’s Economy: GDP and HK Stock Exchange, 1998-2005
Figure 7.2 US Civilian Biodefence Budget: Allocation by Governmental Body ($bn), 2014

*** レポートのキーワード ***

エボラ診断、エボラ治療薬、エボラワクチン

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※H&Iグローバルリサーチは調査サービスを通じて、お客様の海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをご提供しております。
※当市場調査資料"世界のエボラ診断、治療薬、ワクチン市場"は"visiongain社"が調査・発行しており、H&Iグローバルリサーチが販売します。お気軽にお問い合わせください。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。